Literature DB >> 6309665

Effect of cyclosporine on the response of normal human lymphocytes to cytomegalovirus in vitro.

P J Converse, A D Hess, P J Tutschka, G W Santos.   

Abstract

Lymphocytes from healthy volunteers seropositive for cytomegalovirus (CMV) demonstrated strong lymphoproliferative responses to CMV-infected and glutaraldehyde-fixed foreskin fibroblasts (CMVFFx) when cocultured for 6 days. Addition of the immunosuppressive drug cyclosporine (CsA) to the cultures resulted in a 10-fold reduction (P less than 0.001) in counts per minute of [3H]thymidine uptake. The proliferative response to noninfected fixed fibroblasts was also reduced 10-fold. Kinetic studies showed an inhibition of the lymphoproliferative response and not an alteration in the time course kinetics in CsA-treated cultures. Cytotoxicity to CMV-infected and unfixed fibroblasts by lymphocytes primed by CMVFFx in the presence of 0.5 micrograms of CsA per ml was significantly reduced (P less than 0.01) as compared with untreated cultures but remained significantly above background level (P less than 0.01). The cytotoxic response was still present but reduced at concentrations of greater than or equal to 1.0 micrograms/ml. Cytotoxicity to noninfected fibroblasts by CMVFFx-primed lymphocytes could be eliminated by as little as 0.5 micrograms of CsA per ml. Stimulation of lymphocytes by CMVFFx but not by noninfected fixed fibroblasts resulted in the in vitro generation of suppressor cells. CsA at a final concentration of 1.0 or 2.5 micrograms/ml did not significantly impair the induction of cells capable of suppressing the lymphoproliferative response of fresh autologous mononuclear cells to CMVFFx. The findings described above may have important clinical implications in that a degree of protective immunity to CMV-infected cells is maintained even in the presence of CsA.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6309665      PMCID: PMC264630          DOI: 10.1128/iai.41.3.1226-1233.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Use of cryopreserved virus-infected target cells in a lymphocytotoxicity 51Cr release microassay for cell-mediated immunity to cytomegalovirus.

Authors:  Y H Thong; S A Hensen; M M Vincent; D A Fuccillo; W A Stiles; J A Bellanti
Journal:  Infect Immun       Date:  1976-02       Impact factor: 3.441

2.  Cellular immune response to cytomegalovirus infection after renal transplantation.

Authors:  C C Linnemann; C A Kauffman; M R First; G M Schiff; J P Phair
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

3.  Antigens on human fibroblasts demonstrated with HL-A antisera and anti-human lymphocytic sera.

Authors:  E Thorsby; S Lie
Journal:  Vox Sang       Date:  1968       Impact factor: 2.144

4.  Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity.

Authors:  J F Borel
Journal:  Immunology       Date:  1976-10       Impact factor: 7.397

5.  Cytomegalovirus infection in patients receiving immunosuppressive therapy for rheumatologic disorders.

Authors:  J N Dowling; A R Saslow; J A Armstrong; M Ho
Journal:  J Infect Dis       Date:  1976-04       Impact factor: 5.226

6.  Effects of the new anti-lymphocytic peptide cyclosporin A in animals.

Authors:  J F Borel; C Feurer; C Magnée; H Stähelin
Journal:  Immunology       Date:  1977-06       Impact factor: 7.397

7.  Quantification of antigen-reactive cells among human T lymphocytes.

Authors:  M H van Oers; J Pinkster; W P Zeijlemaker
Journal:  Eur J Immunol       Date:  1978-07       Impact factor: 5.532

8.  Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A.

Authors:  R Y Calne; D J White; K Rolles; D P Smith; B M Herbertson
Journal:  Lancet       Date:  1978-06-03       Impact factor: 79.321

9.  Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin-A treatment.

Authors:  C J Green; A C Allison
Journal:  Lancet       Date:  1978-06-03       Impact factor: 79.321

View more
  5 in total

1.  Immune responses to fractionated cytomegalovirus (CMV) antigens after HIV infection. Loss of cellular and humoral reactivity to antigens recognized by HIV-, CMV+ individuals.

Authors:  P J Converse; T E Fehniger; A Ehrnst; O Strannegård; S Britton
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

2.  Qualitative and semiquantitative polymerase chain reaction testing for cytomegalovirus DNA in serum allows prediction of CMV related disease in liver transplant recipients.

Authors:  P C Evans; A Soin; T G Wreghitt; G J Alexander
Journal:  J Clin Pathol       Date:  1998-12       Impact factor: 3.411

3.  Peripheral blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus.

Authors:  C A Stoddart; R D Cardin; J M Boname; W C Manning; G B Abenes; E S Mocarski
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

4.  Mechanism of recovery from acute virus infection. II. Effect of treatment of mice with cyclosporin A on their ability to eliminate the lymphocytic choriomeningitis virus.

Authors:  C Löliger; F Lehmann-Grube
Journal:  Med Microbiol Immunol       Date:  1985       Impact factor: 3.402

5.  Immunological heterogeneity of human monocyte subsets prepared by counterflow centrifugation elutriation.

Authors:  A H Esa; S J Noga; A D Donnenberg; A D Hess
Journal:  Immunology       Date:  1986-09       Impact factor: 7.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.